Pharma Bio Serv Inc (QB) (PBSV) 시세

Some must have liked their presentation yesterday. http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11040949

New post at Seeking Alpha:

http://seekingalpha.com/instablog/24566973-charlie480/2899483-pharma-bio-serv-inc-munger-quality-that-is-obviously-undiscovered


Long

Do you know the float by chance on this one, TIA

PBSV -- gotta love that balance sheet. Over $9 million in cash now and zero debt.

Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2013

http://finance.yahoo.com/news/pharma-bio-serv-announces-results-201500766.html

PBSV reports record quarterly revenues; EPS $.06 vs $.05

CHART
http://stockcharts.com/h-sc/ui?s=pbsv


For the quarter ended 4/13, revenues rose 17% to $8.3M, and net income also rose 17% to $1.39M. Cash rose $1.5M sequentially to $8.5M.





Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2013
DORADO, PUERTO RICO--(Marketwired - Jun 14, 2013) - Pharma-Bio Serv.
(OTCQB: PBSV), a global compliance and validation services consulting
solutions provider, announced net revenues for the three and six months
ended April 30, 2013 of $8.3 and $15.9 million, an increase of approximately
$1.2 and $2.5 million, or 17% and 18%, respectively, when compared to the
same periods last year.
The Company reported net income for the three and six months ended April 30,
2013 of approximately $1.4 and $2.4 million, an increase of $0.2 and $0.1
million, respectively, when compared with the same periods last year.
Revenue growth for the three and six months ended April 30, 2013, over the
same period last year, is mainly attributable to increases in the United
States Consulting market and Lab services, respectively, offset by a
decrease in revenues in the Integratek division and other minor revenue
gains from other Company divisions.
Net income growth, when compared to the same period last year, is
attributable mainly to the aggregate increase in overall gross margins,
offset by the increase in selling general and administrative expenses to
support the favorable revenue trend and business development expenses to
diversify our markets, and the effective income tax rates (including Puerto
Rico favorable tax grants) over income before tax.
Selling, general and administrative expenses for the three and six months
ended April 30, 2013 were approximately $1.4 and $2.7 million, respectively,
a net increase in expenses of approximately $0.4 and $0.8 million,
respectively, as compared to the same periods last year. Business
development and operations support expenses in the Puerto Rico and United
States markets were increased to follow the consulting business favorable
revenue trend. In addition, the Company made business development
investments in Spain to diversify its European division market.
"We are very pleased with our continued performance in expanding our U.S.
presence while efficiently managing our costs," said Nélida Plaza,
Acting Chief Executive Officer, Acting President, Secretary and President of
Puerto Rico Operations. "Our growth is a testament to our ability to
continue to expand our US market base and increase our Lab services
business," she continued.
About Pharma-Bio Serv Inc.
Pharma-Bio Serv is a global compliance and validation services consulting
solutions provider, headquartered in Puerto Rico, with operations in the
U.S, Ireland and Spain. Pharma-Bio Serv's core business is FDA and
international agencies regulatory compliance related services with
integrated portfolio services including microbiological and chemical testing
services for clients in the Pharmaceutical, Biotechnology, Chemical, Medical
Device, Cosmetic, Food and Allied Products industries, at its laboratory
testing facility in Puerto Rico. Services also include "Integratek," an
information technology consulting practice and "Pharma Serv Academy" a
division that provides technical and regulatory standards seminars/training
conducted by industry experts. The Company's global team includes more than
275 leading engineering and life science professionals, quality assurance
managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning
of the U.S. federal securities laws, which statements may include
information regarding the plans, intentions, expectations, future financial
performance, or future operating performance of Pharma-Bio Serv.
Forward-looking statements are based on the expectations, estimates, or
projections of management as of the date of this news release. Although
Pharma-Bio Serv's management believes these expectations, estimates, or
projections to be reasonable as of the date of this news release,
forward-looking statements are inherently subject to significant business
risks, economic and competitive uncertainties, or other contingencies, which
could cause its actual results or performance to differ materially from what
may be expressed or implied in the forward-looking statements. Important
factors that could cause Pharma-Bio Serv's actual results or performance to
differ materially from the forward-looking statements include those set
forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on
Form 10-K for the year ended October 31, 2012 and in its other filings with
the Securities and Exchange Commission, which filings are available on
www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update
or revise any forward-looking statements to reflect subsequent events and
circumstances, except to the extent required by applicable law.
Investor Relations Contact:
Scott Gordon
President
CorProminence LLC
scottg@corprominence.com
631 703 4900

It is looking good!

The ASK looks to be thinning out we have had a buyer patiently picking up some shares lately.
Chart looks ready, just need another very rare PR.

PBSV seems to be perking up a wee bit.

Bout freakin' time!

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2013

DORADO, PR -- (Marketwire) -- 03/20/13 -- Pharma-Bio Serv. (OTCQB: PBSV), a global compliance and validation services consulting solutions provider, announced net revenues of $7.6 million for the quarter ended January 31, 2013, an increase of approximately $1.3 million, or 20%, compared to the same period in 2012.

The Company reported net income for the quarter ended January 31, 2013 of approximately $1 million, a slight decrease of $0.1 million compared to the same period in 2012.

During the quarter ended January 31, 2013, business development and operations support expenses in the Puerto Rico and United States markets were increased to follow the consulting business favorable revenue trend. In addition, during the quarter ended January 31, 2013, the Company made business development investments in Spain to diversify its European division market.

"We are very pleased with our overall performance, particularly in our U.S. Consulting Services," said Nélida Plaza, Acting Chief Executive Officer, Acting President, Secretary and President of Puerto Rico Operations.

About Pharma-Bio Serv Inc.

Pharma-Bio Serv is a global compliance and validation services consulting solutions provider, headquartered in Puerto Rico, with operations in the U.S, Ireland and Spain. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance related services with integrated portfolio services including microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, Chemical, Medical Device, Cosmetic, Food and Allied Products industries, at its laboratory testing facility in Puerto Rico. Services also include "Integratek," an information technology consulting practice and "Pharma Serv Academy" a division that provides technical and regulatory standards seminars/training conducted by industry experts. The Company's global team includes more than 275 leading engineering and life science professionals, quality assurance managers and directors.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this news release. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this news release, forward-looking statements are inherently subject to significant business risks, economic and competitive uncertainties, or other contingencies which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2012 and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

Investor Relations Contact:
Scott Gordon
CorProminence LLC
scottg@corprominence.com

Agreed

The Q report is out. At a quick glance it does not warrant this sell off.

This probably explains some of the margin compression lately. It was in the Q3 report and I ahdn't noticed it before-

"A major customer of Pharma-IR, which represents 10% of the Company’s total consolidated revenue for the nine months ended in July 31, 2012, placed Pharma-IR in a probation/review period which included the reduction of billing rates. Consequently, in order to maintain market share within Ireland, during the three months ended April 30, 2012, Pharma-IR reduced its billable margins to this customer and committed to an improvement on the level of service. Although management is actively pursuing new business development strategies geared to diversify our Ireland market customer base, at this point in time it is uncertain if these strategies will be able to produce the results necessary to offset the loss in the Ireland market margin."


All IMO only.

A share buyback would be nice.

They're doing a nice job of buidling cash now with over $6.5 mill.

Pretty substantial given the market cap and trending higher revs (organic I think) although I would be a little curious about the margin compression. Still a solid Q given the valuation as you mention.

Share buyback??

This company remains drastically undervalued IMO.

About $8.1 mill in revs for Q4 I think in the annual reported but seems margins may have compressed a bit (COGS part of it- not sure if it gets expalined in the verbiage, haven't had time to look yet).

Haven't looked thru it beyond cursory but got $8.1 mill revs and net income of about $1.1 mill for Q4 (about 4.6 cents EPS I think).
Looked like US consulting segment was the largest dollar amount revs increase sequentially.

http://www.sec.gov/Archives/edgar/data/1304161/000135448813000352/pbsv_10k.htm

Continued revs growth but a matter of wondering what is leading to higher COGS.

Edit- just noticed U posted it up on the Swing board already

The trailing PE is now a little over 4 with the latest quarterly earnings of $0.052/share. They now have nine sequential quarters of increasing revenue. This is a great company!

PBSV reported Q1 revenue of $6.360M and diluted EPS of $0.05. That is awesome for a $0.57 stock!

PBSV was mentioned in a Seeking Alpha article:

http://seekingalpha.com/article/429011-abbott-surging-to-80-shocking-naysayers?source=yahoo

They haven't put out PRs as long as I've followed them and I wasn't expecting that to change.

Good report, but no PR to help.

Looks like it came out, saw its' shadow, and will hibernate for another 6 weeks.

The 10-K is out. Q4 revenue was $6,235,875 which was another sequential increase. Diluted EPS came in at $0.037.

Oh gee. Illiquidity or not, Zero point six percent is not exactly a vote of confidence from the board leader. :)

Illiquidity is always a concern for me but it is managed by diversification and sizing of a position. When sizing a position I consider the trading volume, the percentage of my portfolio, and my confidence in the investment thesis. Also, I generally hold over 40 stocks. In the case of PBSV, my position is roughly 0.6% of my portfolio. The other stock you mentioned is 3.0% of my portfolio. Each of these positions is small enough where I can live with the lack of liquidity.

Mike,

How do you position size stocks such as this (and INXSF) if you have to consider the illiquidity. How concerned are you about illiquidity?

Read this on the Swing Trade Board - will be checking it out well.

Thanks for the tip.

All The Best

PBSV is one of my favorites which I think is poised for significant appreciation. They provides technical compliance related consulting services to the pharmaceutical, biotechnology, medical device, and chemical manufacturing industries. Here are some reasons I like PBSV:

1. PBSV has had 6 quarters of sequential growth in both revenue and earnings!

2. In the most recent quarter they made $0.067/share. Using their normal tax rate going forward, however, it would have been $0.044.
I expect them to continue to grow but even if earnings stayed flat they would make $0.18/share in the next 4 quarters. At $0.70/share they are quite cheap!

3. PBSV has a very strong balance sheet with a book value of $0.36/share and cash of $0.18/share.

4. They have a number of growth initiatives underway including branching out into IT services.

There is a 50K share bid at $0.60 for PBSV!

Here is a link to the filing:

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=8147583-943-85052&type=sect&dcn=0001354488-11-003435

PBSV reports a blowout quarter with revenue of $5,517,832 and diluted EPS of $0.067. This is the 6th sequential quarter of growth in revenue and earnings!

It traded up $0.32 to $0.75!!!!

The volume on PBSV is almost 10x the average daily volume!

PBSV is one of my favorites and I think is poised for significant growth. They provides technical compliance related consulting services to the pharmaceutical, biotechnology, medical device, and chemical manufacturing industries. Here are some reasons I like PBSV:

1. PBSV has had 5 quarters of sequential growth in both revenue and earnings! In the most recent quarter they made $0.021/share yet they last traded at only $0.40.

2. PBSV has a very strong balance sheet with a book value of $0.29/share and cash of $0.13/share.

3. PBSV is hiring rapidly. They had 95 employees as of the end of 2010 and have 37 open positions listed on their web site.
http://www.pharmabioserv.com/Careers/tabid/213/language/en-US/Default.aspx

4. They have a number of growth initiatives underway including branching out into IT services.

LOL

Bout freakin' time...been waiting ever since this board was created.

DD coming soon!